Pfizer's Drug Problem: Lipitor
Since Merck's (MRK) Zocor lost patent protection in June 2006, generic versions of the cholesterol fighter have been taking pieces out of Lipitor's U.S. market share week after week.
Lipitor's importance to its maker, Pfizer (PFE), is readily apparent -- not only is it the company's biggest product, it's also the world's top-selling prescription drug. The continuing challenge is beating back increasingly fierce competition.
"Pfizer is in a tough spot," says Joseph Tooley of A.G. Edwards. "Generic Zocor is a game-changer. It's growing at a rapid pace."
For the four weeks ended June 1, Lipitor had a 32.7% market share of U.S. prescriptions, down from 40.9% a year earlier. Generic Zocor now has a 23% share, according to a recent report from Tooley's firm, citing data from the medical-products-tracking firm IMS Health.At the same time, Lipitor's dominance is shrinking while the total market is growing. U.S. prescription volume rose 10.3% in the past year, but Lipitor's volume dropped 12%. Pfizer has regained a tiny amount of lost prescriptions thanks to Caduet, which combines Lipitor and the blood-pressure drug Norvasc. Still, Caduet's market share is up to only 1.6% from 1.2% a year ago. "Caduet appears to be gaining some traction," says Tooley, noting that the drug remains a small player. Tooley, who doesn't own shares, has a hold rating on Pfizer. His firm has had a recent noninvestment banking relationship with the drugmaker. Click here for TheStreet.com TV video of this story.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV